Navigation Links
'Clinical and Economical Considerations For IV Push Drug Delivery' by Industry Expert Richard Rosenfeld Is Now Accessible on Expert411.com for Media and Professional Use
Date:12/27/2007

ENGLEWOOD, Colo., Dec. 27 /PRNewswire/ -- The "Clinical and Economical Considerations For IV Push Drug Delivery" technical paper -- authored by Industry Expert Richard Rosenfeld, RPh, MBA, for Baxa Corporation -- is now accessible at http://expert411.com/_wsn/page16.html for media and professional reference. The paper is an overview of the historical background for IV push and a model for implementation of a successful program.

IV push of cephalosporin antibiotics and other drugs is an alternative method of administration that can be safe, efficacious and cost effective. This paper concentrates on IV push of cefazolin as a case study, since it is a high-use cephalosporin with physical and chemical properties similar to other drugs that can be administered by the IV push method.

Rosenfeld has personally implemented the use of IV push antibiotics within two hospital systems. During the first year that this IV push program was in place, more than 50,000 doses of cefazolin were administered by the IV push method with no occurrences of phlebitis or adverse drug events directly associated with the change in the administration method of this drug. The paper discusses the economical advantages of moving to IV push, as well as the resulting nurse satisfaction and patient benefits seen through the resulting research followup.

Executive Director of Pharmacy Management for the Scripps Health Hospital System in San Diego, CA, Rosenfeld has responsibility for all system pharmacy services through his position with Cardinal Technology and Services. Prior to joining the Scripps Health team, he served as a consultant at Sharp Healthcare, a five-hospital IDN in San Diego, California, where the IV push method of administration for cephalosporins was implemented.

Rosenfeld earned a BS in Pharmacy from Ferris State University and a BA in Chemistry from San Diego State University. He holds
'/>"/>

SOURCE Baxa Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cqsxmg/gene_therapy ) ... "Gene Therapy - Technologies, Markets and Companies" ... therapy are difficult to estimate as there is only ... in China since 2004. Gene ... estimates are based on epidemiology of diseases to be ...
(Date:9/2/2015)... Biovista Inc. is glad to ... BeHEARD science challenge, a global competition hosted by the ... to the latest life science innovations and technologies. ... analytics capability to support Steven Laffoon and ... of Niemann-Pick Disease Type A (NPA), a rare and ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... , Sept. 2, 2015 Aytu BioScience, Inc. ... treatments for urological and related conditions, announced today that ... private placement convertible note financing, raising a total of ... totaling $3.175 million. Josh Disbrow ... this private placement are intended to be used to ...
Breaking Biology Technology:Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3
... , , ST. LOUIS, Aug. ... Board of Directors meeting held today, the Directors declared a quarterly ... on September 15, 2009 to shareholders of record on September 1, ... is a leading Life Science and High Technology company. Our chemical ...
... Baltimore Convention Center - September 21-23, 2009 ... will attract more than 1,200 experts from more than 25 countries ... speakers, including governors, federal officials, and top researchers and scientists and ... stories. This is your chance to meet and talk to ...
... Aug. 11 ValGenesis, Inc., a leading provider ... availability of Microsoft SharePoint Server integration with the ... productivity specifically for regulated Pharmaceuticals, Biotech and Medical ... access, retrieval and storage of corporate validation data ...
Cached Biology Technology:World Stem Cell Summit to Be Held in Baltimore 2ValGenesis, Inc. Announces Integration of ValGenesis Solution with Microsoft SharePoint Server 2
(Date:9/2/2015)... , September 2, 2015 ... security purpose implied in a system which uses ... voice, signature, iris, vein, DNA and finger print. ... forced to develop such system which provides high ... password, PIN, Patterns and tokens are vulnerable to ...
(Date:8/28/2015)... , August 28, 2015 ... and Training Market by Assessment Type (Pen & Paper ... Brain Training, Corporate Learning, Academic Research), Vertical and Region ... Assessment and Training Market to grow from USD 2.4 ... at a Compound Annual Growth Rate (CAGR) of 25.6% ...
(Date:8/24/2015)... Aug. 24, 2015  Based on its recent analysis of ... the 2015 African Biometrics Company of the Year Award. DERMALOG ... commercial success in Africa . It has ... it has implemented one of the largest biometric mass applications ... as the Central Bank of Nigeria ...
Breaking Biology News(10 mins):Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6
... The Translational Genomics Research Institute (TGen), Scottsdale Healthcare and ... help cancer patients by stimulating the immune system. ... at TGen Clinical Research Services at Scottsdale Healthcare, a ... and at Mayo Clinic in Arizona. Dr. Ramesh ...
... that we can only learn how to do something by ... light of recent discoveries in neuroscience. It turns out that ... mirror neurons that fire in the same pattern whether performing ... an important role in learning motor tasks involving hand eye ...
... in The Netherlands will award an honorary doctorate to ... BioNanotechnology in Medicine, at Northwestern University, Chicago. He will ... Friday, 24 April 2009. Stupp (57) is being honored ... for complex molecular systems in biomedical technology. His findings ...
Cached Biology News:TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims 2How mirror neurons allow us to learn and socialize by going through the motions in the head 2Samuel Stupp to receive honorary doctorate from TU/e 2
Request Info...
Ultra-sensitive, non-radioactive measurement of COX-I and COX-II activity...
Recombinant Ovine (Sheep) Growth Hormone, Ultra Pure...
Mouse Granzyme D MAb (Clone 190617)...
Biology Products: